Involvement of the Catecholamine Pathway in Glioblastoma Development
Open Access
- 4 March 2021
- Vol. 10 (3), 549
- https://doi.org/10.3390/cells10030549
Abstract
Glioblastoma (GBM) is the most aggressive tumor of the central nervous system (CNS). The standard of care improves the overall survival of patients only by a few months. Explorations of new therapeutic targets related to molecular properties of the tumor are under way. Even though neurotransmitters and their receptors normally function as mediators of interneuronal communication, growing data suggest that these molecules are also involved in modulating the development and growth of GBM by acting on neuronal and glioblastoma stem cells. In our previous DNA CpG methylation studies, gene ontology analyses revealed the involvement of the monoamine pathway in sequential GBM. In this follow-up study, we quantitated the expression levels of four selected catecholamine pathway markers (alpha 1D adrenergic receptor—ADRA1D; adrenergic beta receptor kinase 1 or G protein-coupled receptor kinase 2—ADRBK1/GRK2; dopamine receptor D2—DRD2; and synaptic vesicle monoamine transporter—SLC18A2) by immunohistochemistry, and compared the histological scores with the methylation levels within the promoters + genes of these markers in 21 pairs of sequential GBM and in controls. Subsequently, we also determined the promoter and gene methylation levels of the same markers in an independent database cohort of sequential GBM pairs. These analyses revealed partial inverse correlations between the catecholamine protein expression and promoter + gene methylation levels, when the tumor and control samples were compared. However, we found no differences in the promoter + gene methylation levels of these markers in either our own or in the database primary–recurrent GBM pairs, despite the higher protein expression of all markers in the primary samples. This observation suggests that regulation of catecholamine expression is only partially related to CpG methylation within the promoter + gene regions, and additional mechanisms may also influence the expression of these markers in progressive GBM. These analyses underscore the involvement of certain catecholamine pathway markers in GBM development and suggest that these molecules mediating or modulating tumor growth merit further exploration.Funding Information
- University of Pecs, Dr. Szolcsányi János Research Grant (KA-2019-42, 871075, 754432)
This publication has 78 references indexed in Scilit:
- GRK2: multiple roles beyond G protein-coupled receptor desensitizationTrends in Pharmacological Sciences, 2012
- Molecular Mechanisms of RNA-Triggered Gene Silencing MachineriesAccounts of Chemical Research, 2012
- Suppression of G-protein–Coupled Receptor Kinase 3 Expression Is a Feature of Classical GBM That Is Required for Maximal GrowthMolecular Cancer Research, 2012
- Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applicationsBioinformatics, 2011
- The immunoregulatory role of dopamine: An updateBrain, Behavior, and Immunity, 2010
- The complex G protein‐coupled receptor kinase 2 (GRK2) interactome unveils new physiopathological targetsBritish Journal of Pharmacology, 2010
- Behavioral functions of the mesolimbic dopaminergic system: An affective neuroethological perspectiveBrain Research Reviews, 2007
- Epigenetic regulation of human α1d‐adrenergic receptor gene expression: a role for DNA methylation in Spl‐dependent regulationThe FASEB Journal, 2007
- Olig2-Regulated Lineage-Restricted Pathway Controls Replication Competence in Neural Stem Cells and Malignant GliomaNeuron, 2007
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005